




Neogap launches collaboration with Weill Cornell Medicine through Vinnova-funded project

Neogap Therapeutics AB, a Swedish biotechnology company developing personalised cancer immunotherapy, has been awarded a SEK 1 million grant from Vinnova, Sweden's innovation agency, to initiate a collaborative project with Weill Cornell Medicine in New York, U.S. The initiative will explore pathways for conducting future clinical studies in the United States.



The collaboration focuses on advancing Neogap's novel adoptive T-cell therapy, pTTL (personalised Tumour Trained Lymphocytes), which uses tumour-draining lymph nodes as a source of tumour-reactive T cells and applies a multi-neoantigen targeting approach. The aim is to make personalised immunotherapy for solid cancers more efficient and broadly accessible.

Combining Neogap's clinical and technological expertise with Weill Cornell Medicine's experience in TIL therapy, lung cancer surgery, and translational immuno-oncology – and specifically drawing on Dr Jonathan Villena-Vargas's insights into tumour-draining lymph nodes – the project will assess how Neogap's personalised cell therapy may be integrated into clinical practice and prepare for the potential inclusion of US sites in upcoming Phase II trials.

“Collaborating with Weill Cornell Medicine is an important step in our international development. It allows us to connect Neogap's clinical progress in Sweden with leading US expertise in cell therapy and translational oncology. This project not only prepares us for future clinical trials in the United States but also reinforces the global relevance of our novel personalised immunotherapy,” said Samuel Svensson, CEO of Neogap Therapeutics.

“We’re looking forward to applying our tumor-draining lymph node T-cell expertise to investigate a potential strategy to directly impact personalized treatment for patients with solid cancers,” said Jonathan Villena-Vargas, Assistant Professor of Clinical Cardiothoracic Surgery at Weill Cornell Medicine.

This collaboration marks a significant step in Neogap’s strategy to expand its clinical and regulatory footprint internationally and contributes to aligning Swedish and US approaches to regulatory, data, and material transfer in personalised immunotherapy. Funded by Vinnova under its programme for international research and innovation collaboration, the project supports the expansion of Neogap’s T-cell therapy through Sweden–US collaboration.

About Neogap’s cell-based immunotherapy, pTTL

pTTL (personalised Tumour Trained Lymphocytes) is a personalised cell therapy that enhances the patient’s own T cells to fight cancer. It combines advanced DNA sequencing with T-cell expansion to deliver a precision treatment for solid tumours. The therapy is powered by Neogap’s proprietary technologies, PIOR® and EpiTCer®, and is currently being evaluated in a Phase I/II clinical trial for advanced colorectal cancer.



Project reference number: 190185439 – NEOpTTL. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.

For more information, please contact:

Samuel Svensson, CEO

Email: samuel.svensson@neogap.se

Phone: +46 733 54 21 94

About Neogap Therapeutics

Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient's own cells. The therapy is based on the company's two technologies PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its cutting-edge research, please visit neogap.se and follow Neogap on [LinkedIn](#).